The REPROCELL Blog

New publication by Roche on diarrheal toxicity induced by anti-HER2/3 combination therapy includes REPROCELL human fresh tissue data

[fa icon="calendar'] Jun 26, 2018 5:46:01 AM / by Dr David Bunton posted in Human Tissues, Ussing Chambers

[fa icon="comment"] 0 Comments

A publication in Molecular Cancer Therapeutics has shed new light on the mechanisms by which anti-HER2/3 combination therapies can cause diarrhea.

Continue reading [fa icon="long-arrow-right"]

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

[fa icon="calendar'] Jun 21, 2018 8:44:03 AM / by Chirag Tawde posted in Drug Discovery, Human Tissues, primary cells

[fa icon="comment"] 0 Comments

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.

Continue reading [fa icon="long-arrow-right"]

Join REPROCELL at ISSCR 2018 in Melbourne, Australia

[fa icon="calendar'] Jun 15, 2018 8:07:06 AM / by Robert Annand posted in Stem Cells, ISSCR

[fa icon="comment"] 0 Comments

ISSCR (the International Society for Stem Cell Research) is the preeminent stem cell research group in the world. ISSCR is holding its 2018 Annual Meeting in Melbourne, Australia – and REPROCELL will be there.

Join us 20-23 June at booth 74 and learn how we can help you with your stem cell needs.

Continue reading [fa icon="long-arrow-right"]

REPROCELL's footprint extends to serve life sciences in India

[fa icon="calendar'] Jun 13, 2018 11:07:41 AM / by Rama Modali posted in Human Tissues, Stem Cells, Genome Sequencing, Bioinformatics, Global Expertise

[fa icon="comment"] 0 Comments

REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.

Continue reading [fa icon="long-arrow-right"]

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

[fa icon="calendar'] May 25, 2018 11:03:43 AM / by Dr David Bunton

[fa icon="comment"] 0 Comments

The use of animals to predict the risk of adverse effects in humans is a long-standing debate within Pharma and also in society at large. Moreover, safety issues leading to clinical attrition remain a problem and a major financial drain on Pharma.

Continue reading [fa icon="long-arrow-right"]

Factors to consider when planning a iPSC reprogramming project

[fa icon="calendar'] May 18, 2018 8:03:40 AM / by Dr Sarah Eminli-Meissner

[fa icon="comment"] 0 Comments

When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.

Continue reading [fa icon="long-arrow-right"]

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

[fa icon="calendar'] Apr 18, 2018 4:44:17 AM / by Simon Padbury

[fa icon="comment"] 0 Comments

REPROCELL Europe’s CEO, Dr David Bunton, was part of last week's  trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP.

Continue reading [fa icon="long-arrow-right"]

Characterization of iPSCs by Immunocytochemistry

[fa icon="calendar'] Apr 5, 2018 12:20:38 PM / by Zara Puckrin posted in Drug Discovery, Stem Cells

[fa icon="comment"] 0 Comments

As part of our contract services at REPROCELL, we offer induced pluripotent stem cell (iPSC) characterization by immunocytochemistry (ICC). Planning ICC can be tricky, as it requires careful selection of compatible antibodies and fluorochromes. However, if successful, the results are fantastic! Don’t waste valuable research time performing ICC, and let our experts do the work for you!

Continue reading [fa icon="long-arrow-right"]

The Benefits of Human Tissue to Drug Discovery and Development

[fa icon="calendar'] Mar 27, 2018 7:00:00 AM / by Karen Mcaulay posted in Drug Discovery, Human Tissues

[fa icon="comment"] 0 Comments

Progressive and innovative Pharmaceutical and Biotechnology companies ask themselves several key questions when it comes to Drug Discovery and Development:

• How and where can we be research smarter? 
• How can we reduce uncertainty? 
• How can we better predict efficacy and safety? 
• How can we reduce costs?

One route to making the drug discovery process smarter and more efficient is to use human tissue at one or more stages in the development process.

Continue reading [fa icon="long-arrow-right"]

REPROCELL’s David Bunton addresses the Scottish Parliament

[fa icon="calendar'] Mar 21, 2018 11:58:30 AM / by Abbie Wishart posted in Drug Discovery, Scotland's Economic Performance, Research & Development, Government Partnership, SME

[fa icon="comment"] 0 Comments

On Tuesday 20th March 2018 REPROCELL Europe Ltd’s CEO Dr David Bunton appeared in front of the Economy, Jobs and Fair Work Committee at the Scottish Parliament to discuss Scotland’s Economic performance.  He was also joined by:

• Dr Diane Harbison, CEO, of Stratified Medicine Scotland

• Claire Mack, CEO, of Scottish Renewables

• Gareth Wynn, Stakeholder and Communications Director, Oil & Gas UK

Continue reading [fa icon="long-arrow-right"]